Calviri, Inc.

Calviri, Inc. Receives Exclusive Patent License to Immunosignature Technology, Strengthening Its Disease Diagnostic Capabilities

Retrieved on: 
Tuesday, October 13, 2020
Other Health, Pharmaceutical, Other Technology, Research, Oncology, Software, Infectious diseases, Hospitals, Genetics, Data management, Stem cells, Science, Technology, General Health, FDA, Biotechnology, AIDS, Health, Immune system, Immunosignature, Branches of biology, Antibody, Biology, Calviri, Inc., Skysong Innovations

The Immunosignature Technology was invented and originally developed by Stephen Albert Johnston, now CEO of Calviri, and his colleagues at ASU.

Key Points: 
  • The Immunosignature Technology was invented and originally developed by Stephen Albert Johnston, now CEO of Calviri, and his colleagues at ASU.
  • The platform uses hundreds of thousands of chemically diverse peptides to provide an unbiased profile of an individuals antibody repertoire.
  • Initially intended as simply a diagnostic tool to detect disease onset, additional work has shown its potential for measuring disease severity and response to therapies.
  • Calviri is dedicated to detecting and treating disease early, said Dr. Kathryn Sykes, VP of Research and Product Development.

Calviri Appoints Michael Chambers to Board of Directors

Retrieved on: 
Tuesday, August 18, 2020
Oncology, Health, Genetics, Clinical trials, Pharmaceutical, Biotechnology, Vaccination, Vaccine, Virology, Fargo, North Dakota, Calviri, Inc., Aldevron

announces today the appointment of Michael Chambers to the Calviri Board of Directors.

Key Points: 
  • announces today the appointment of Michael Chambers to the Calviri Board of Directors.
  • Until recently Chambers held the position of CEO at Aldevron (Fargo, ND); he remains Chairman of the Board.
  • Chambers broad experience and success in the biotechnology industry will contribute greatly to new trials as Calviri works toward its diagnostic and vaccine product goals.
  • I have known Michael for over 20 years and have been amazed at what he has accomplished at Aldevron.

Cancer Vaccine Start Up, Calviri, Closes Successful Seed Funding Round

Retrieved on: 
Thursday, April 2, 2020
Biotechnology, Pharmaceutical, Health, Oncology, Finance, Money, Economy, Arizona State University, The Biodesign Institute, Angel investor, Seed money, Vaccine, Calviri, Inc., Arizona State University, Skysong Innovations

Calviri, Inc., a biotech startup spun out of Arizona State University Biodesign Institute, focused on ending deaths from cancer, today announced the closing of $2.25 million in seed round funding.

Key Points: 
  • Calviri, Inc., a biotech startup spun out of Arizona State University Biodesign Institute, focused on ending deaths from cancer, today announced the closing of $2.25 million in seed round funding.
  • The funding is from five private investors including Dr. Jacque Sokolov, a Calviri Board member, and Dr. Mitzi Krockover.
  • This process is the basis for the design of off-the-shelf vaccines for any cancer, as well as diagnostics for the early detection of any cancer.
  • Kathryn Sykes, VP of Research and Product Development, stated, We will use the funding to demonstrate the strengths of this unique technology.